Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000522819
Ethics application status
Approved
Date submitted
2/04/2012
Date registered
16/05/2012
Date last updated
13/07/2016
Type of registration
Prospectively registered

Titles & IDs
Public title
Phase I/II BNC105P combination study in partially platinum sensitive ovarian cancer patients in first or second relapse
Scientific title
Phase I/II BNC105P combination study, evaluating recommended dose of BNC105P and objective response rate, in partially platinum sensitive ovarian cancer patients in first or second relapse
Secondary ID [1] 280266 0
ANZGOG-1103
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ovarian cancer 286214 0
Condition category
Condition code
Cancer 286428 286428 0 0
Ovarian and primary peritoneal

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Phase I: Carboplatin AUC 4 day 1 given IV over 60 minutes, Gemcitabine escalations 800 and 1000 mg/m2 days 1 and 8, given IV over 30 minutes, BNC105P escalations at 8, 12 or 16mg/m2 days 2 and 9, given IV over 10 minutes, all every 21 days, for 6 cycles, followed by single agent maintenance BNC105P for a maximum of 6 additional cycles at 16 mg/m2 on days 2 and 9.
Phase II: Carboplatin AUC 4 day 1 IV over 60 minutes, Gemcitabine 800 or 1000 mg/m2 days 1 and 8 IV over 30 minutes as determined in the Phase I component, given with OR without BNC105P at previously defined MTD on days 2 and 9, all every 21 days for 6 cycles, followed by a maximum of 6 cycles of single agent BNC105P at 16 mg/m2.
Intervention code [1] 284615 0
Treatment: Drugs
Comparator / control treatment
Phase I: single arm dose finding study

Phase II comparator: Carboplatin AUC 4 on day 1, gemcitabine 800 or 1000 mg/m2 on days 1 and 8 of a 21 day cycle for a maximum of 6 cycles.
Control group
Active

Outcomes
Primary outcome [1] 286871 0
Phase I = recommended dose of BNC105P based on acceptable number of dose limiting toxicities as outlined in protocol
Timepoint [1] 286871 0
22 days after last patient has completed treatment with each dose
Primary outcome [2] 286872 0
Phase II = Overall Response Rate as determined by RECIST and/or GCIG criteria for CA125 response
Timepoint [2] 286872 0
After a minimum of 12 months follow up has been completed for all patients
Secondary outcome [1] 296872 0
Progression free survival (PFS) and overall survival (OS)
Timepoint [1] 296872 0
After a minimum of 12 months follow up has been completed for all patients
Secondary outcome [2] 296873 0
Adverse event rates graded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Timepoint [2] 296873 0
30-42 days after last dose
Secondary outcome [3] 296874 0
Effects on aspects of health related quality of life (HRQL measured with FOSI and MOST)
Timepoint [3] 296874 0
30-42 days after last dose

Eligibility
Key inclusion criteria
Phase I only
1. Histologically or cytologically proven diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer, including all histological subtypes and carcinosarcoma.
2. Progression-free interval > 4 months (as per GCIG definition of progression) after first or second line platinum (cisplatin or carboplatin) based chemotherapy.
3. Performance status of ECOG 0-1.

Phase II only
1. Histologically proven diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.
2. Progression-free interval between 4 to 9 months after first line chemotherapy or 4 to 12 months after second-line chemotherapy with a platinum (cisplatin or carboplatin) based regimen.
3. Subjects must have progressed (based on GCIG CA125 and/or RECIST criteria) after last platinum based regimen
4. Subjects must be assessable for response based on GCIG CA125 and/or RECIST criteria.
5. Subjects with clinically evident ascites and/or pleural effusions must be assessable by RECIST.
6. If the calculated GFR is 50 - 54 ml/min an isotopic GFR may be performed. If the isotopic GFR is > 55ml/min, the patient will be eligible for the study but the calculated GFR will be used for dose calculation.
7. Performance status of ECOG 0-2
8. Study treatment both planned and able to start within 7 days of randomisation
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Phase II only
1. Carcinosarcoma and mucinous carcinoma

Phase I and II
1. Non-epithelial ovarian cancer and ovarian tumours of low malignant potential (borderline tumours)
2. More than two prior chemotherapy regimens for ovarian cancer (excluding hormonal therapy or biologic agents).
3. Any prior chemotherapy for other cancers, but >10 years permitted for phase II only, except for high dose chemotherapy/autologous or allogeneic transplantation
4. Chemotherapy within 20 days prior to registration.
5. Hormonal therapy or biologic therapy within 28 days prior to registration
6. Concurrent treatment with any experimental drugs or other anti-cancer therapy.
7. Concurrent treatment with clopidogrel, ticlopidine, persantin and other antiplatelet agents
8. Radiotherapy within 21 days prior to registration, or to greater than 15% of the bone marrow.
9. Persistent toxic effects of previous chemotherapy of greater than grade 1 severity

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Phase I Nonrandomised. Allocation to dosing levels in consultation with Trial Steering Committee

Phase 2 Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/06/2012
Actual
30/07/2012
Date of last participant enrolment
Anticipated
31/12/2013
Actual
10/05/2013
Date of last data collection
Anticipated
Actual
9/04/2014
Sample size
Target
134
Accrual to date
Final
15
Recruitment in Australia
Recruitment state(s)
NSW,VIC,QLD
Recruitment outside Australia
Country [1] 4236 0
United States of America
State/province [1] 4236 0
Indiana

Funding & Sponsors
Funding source category [1] 285028 0
Commercial sector/Industry
Name [1] 285028 0
Bionomics Ltd
Country [1] 285028 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW 1450
Country
Australia
Secondary sponsor category [1] 283892 0
None
Name [1] 283892 0
Address [1] 283892 0
Country [1] 283892 0
Other collaborator category [1] 260696 0
Other Collaborative groups
Name [1] 260696 0
Australia New Zealand Gynaecological Oncology Group
Address [1] 260696 0
Locked Bag 77
Camperdown
NSW 1450
Country [1] 260696 0
Australia
Other collaborator category [2] 260697 0
Other Collaborative groups
Name [2] 260697 0
Hoosier Oncology Group
Address [2] 260697 0
351 W. 10th Street, Suite 330
Indianapolis, IN 46202
Country [2] 260697 0
United States of America

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 287030 0
Cancer Institute NSW Clinical Research Ethics Committee
Ethics committee address [1] 287030 0
Ethics committee country [1] 287030 0
Australia
Date submitted for ethics approval [1] 287030 0
Approval date [1] 287030 0
24/02/2012
Ethics approval number [1] 287030 0
2011C/12/178
Ethics committee name [2] 295465 0
Sydney Local Health District Human Research Ethics Committee
Ethics committee address [2] 295465 0
Ethics committee country [2] 295465 0
Australia
Date submitted for ethics approval [2] 295465 0
14/08/2013
Approval date [2] 295465 0
19/08/2013
Ethics approval number [2] 295465 0
X13-0158 & HREC/13/RPAH/317

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34013 0
Prof Danny Rischin
Address 34013 0
Peter MacCallum Cancer Centre
2 St Andrews Place, East Melbourne VIC 3002
Country 34013 0
Australia
Phone 34013 0
+61 3 9656 1111
Fax 34013 0
Email 34013 0
danny.rischin@petermac.org
Contact person for public queries
Name 17260 0
ANZGOG trials
Address 17260 0
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW 1450
Country 17260 0
Australia
Phone 17260 0
+61 2 9562 5000
Fax 17260 0
+61 2 9562 5094
Email 17260 0
anzgog1103@ctc.usyd.edu.au
Contact person for scientific queries
Name 8188 0
ANZGOG trials
Address 8188 0
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW 1450
Country 8188 0
Australia
Phone 8188 0
+61 2 9562 5000
Fax 8188 0
+61 2 9562 5094
Email 8188 0
anzgog1103@ctc.usyd.edu.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.